Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Everest Medicines Ltd. ( (HK:1952) ) has issued an announcement.
Everest Medicines Limited has released its audited annual results for the year ended 31 December 2025, confirming that the full 2025 annual report is now available in both Chinese and English. The results, reviewed by the audit committee and Ernst & Young, will be accessible online, with printed reports delivered to shareholders and electronic versions posted by the end of April 2026, reinforcing the company’s compliance and transparency obligations under Hong Kong listing rules.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$36.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed on the Hong Kong Stock Exchange, focusing on the development and commercialization of innovative medicines. The group operates through a network of subsidiaries and is overseen by a board comprising executive, non-executive and independent non-executive directors based in Hong Kong and the Cayman Islands.
Average Trading Volume: 3,174,542
Technical Sentiment Signal: Sell
Current Market Cap: HK$12.47B
For an in-depth examination of 1952 stock, go to TipRanks’ Overview page.